C.R. Bard Inc. (NYSE:BCR) Chairman Timothy M. Ring sold 110,000 shares of the company’s stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $228.96, for a total value of $25,185,600.00. Following the transaction, the chairman now directly owns 96,030 shares of the company’s stock, valued at $21,987,028.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of C.R. Bard Inc. (NYSE:BCR) opened at 223.74 on Friday. The firm has a market capitalization of $16.43 billion, a P/E ratio of 52.03 and a beta of 0.57. The firm’s 50-day moving average is $221.47 and its 200 day moving average is $218.96. C.R. Bard Inc. has a 52 week low of $172.21 and a 52 week high of $239.43.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.47 by $0.07. The company earned $931.50 million during the quarter, compared to analyst estimates of $915.22 million. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $2.27 earnings per share. Equities research analysts forecast that C.R. Bard Inc. will post $10.17 EPS for the current fiscal year.
BCR has been the subject of several recent research reports. Wells Fargo & Co. raised C.R. Bard from a “market perform” rating to an “outperform” rating in a report on Friday, September 16th. Leerink Swann reaffirmed a “market perform” rating and set a $233.00 target price (down from $240.00) on shares of C.R. Bard in a report on Thursday, July 28th. Barclays PLC boosted their price objective on C.R. Bard from $224.00 to $235.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 27th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, Morgan Stanley reiterated a “hold” rating and set a $240.00 price objective on shares of C.R. Bard in a research report on Thursday, July 28th. Thirteen research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $233.00.
Several hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC purchased a new stake in C.R. Bard during the first quarter valued at $101,000. JPMorgan Chase & Co. raised its stake in C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock valued at $135,290,000 after buying an additional 520,319 shares during the last quarter. BlackRock Japan Co. Ltd raised its stake in C.R. Bard by 5.6% in the first quarter. BlackRock Japan Co. Ltd now owns 99,002 shares of the company’s stock valued at $20,065,000 after buying an additional 5,269 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in C.R. Bard by 4.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,234,725 shares of the company’s stock valued at $452,912,000 after buying an additional 98,144 shares during the last quarter. Finally, BlackRock Fund Advisors raised its stake in C.R. Bard by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,886,656 shares of the company’s stock valued at $382,369,000 after buying an additional 147,571 shares during the last quarter. 87.90% of the stock is owned by institutional investors.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.